의료기술과 보건정책: 기술 확산과 정책 대안 = Technology and Health Policy -Rapid Technology Diffusion and Policy Options in Korea-

다국어 초록 (Multilingual Abstract)

Medical technology has played an increasingly important role in health care. New high-tech medical devices, brand-name drugs and medical procedures contribute to better health outcomes and improved quality of life. At the same time, however, heavy reliance on high-technology medical care results in the increase in the intensity of care and health care expenditure. This paper reviews both theoretical issues associated with the diffusion of medical technology in general and the policy issues of Korea along with a few OECD countries. Korea has experienced a very rapid diffusion of high-tech medical care due to the perverse financial incentive of providers associated with the fee-for-service system, dominance of private for-profit providers of health care, and the lack of regulation on the adoption of medical technology. Since the rapid diffusion of medical technology is driven by providers rather than by consumers, public policy should focus on health care providers such as price regulation, payment system reform, planning and regulation of technology adoption, economic evaluation, and safety regulation. Effective strategy is also in need to minimize the social costs associated with the implementation of payment system reform and economic evaluation mechanism for medical technology, considering the opposition by vested interest groups.

참고문헌 (Reference)

1 Grabowski, "and price competition in pharmaceuticals after the 1984 drug act Journal of Law and Economics" 331-350, 1992

2 Baumgardner, "The Interaction between Forms of Insurance Contract and Types of Technical Change in Medical Care Rand Journal of Economics" 36-53, 1991

3 Kwon,S, "Pharmaceutical Reform and Physician Strikes in Korea Separation of Drug Prescribing and Dispensing" 57 (57): 529-538, 2003

4 Bae,E, "Pharmaceutical Pricing in Korea, Korea Institute of Health and Social Affairs" 2001

5 Danzon, P, "Pharmaceutical Price Regulation: National Policies versus Global Interests" Washington, DC, AEI Press 1997

6 Davis,P, "Managing Medicines: Public Policy and Therapeutic Drugs" Philadelphia: Open University Press 1997

7 Cutler, D, "Is Technological Change in Medicine Worth It?" 20 (20): 11-30, sep/oct2001

8 Newhouse, "How Much Welfare Loss?' Journal of Economic Perspectives" 3-21, 1991

9 Cutler,D, "Equality, Efficiency, and Market Fundamentals: The Dynamics of International Medical-Care Reform," XL : 881-906, 2002

10 Koenig,H, "Diffusion of High-Cost Medical Devices Regulations in Four European Union Member States, Health Care and its Financing in the Single European Market" Amsterdam: IOS Press 150-166, 1998

11 Danzon, P, "Cross-national price difference for pharmaceuticals: How large and why?" 19 (19): 159-195, 2000

12 Finkler, "Cost Accounting for Health Care Organizations" 1993

13 Lichtenberg, F, "Are the benefits of newer drugs worth their costs? Evidence from the 1996 MEPS" 20 (20): 241-252, sep/oct2001

14 Weisbrod, "AN Essay on Technological Change Quality of Care Journal of Economic Literature" 523-552, 1991